RMC-6236

Dana-Farber Cancer Institute researchers are presenting multiple groundbreaking studies on head and neck, breast, and lung cancers at the 2025 AACR Annual Meeting in Chicago from April 25-30.

A groundbreaking experimental drug, daraxonrasib by Revolution Medicines, demonstrates encouraging results in treating late-stage pancreatic cancer patients, offering new hope in a traditionally difficult-to-treat disease.

Phase 1 trial of daraxonrasib (RMC-6236) in RAS-mutant pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging early results.

Daraxonrasib demonstrates encouraging antitumor activity and manageable safety in RAS-mutated pancreatic ductal adenocarcinoma (PDAC), showing potential to inhibit major RAS variants.

Dana-Farber Cancer Institute has established the Center for RAS Therapeutics to develop drug therapies for RAS-driven cancers, which are linked to lower survival rates.